KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Journal of Pharmacy / 2021 / Cilt: 51 - Sayı: 1

Preparation and in vitro studies of fixed-dose tablet combination of repaglinide and metformin

Sinem ŞAHİN
Burcu MESUT
M. Ezgi DURGUN
Esher ÖZÇELİK
Yıldız ÖZSOY
Sayfa
26–34
Yayın Tarihi
2021-04-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Thus, an alternative product to the market product was developed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background and Aims: The study aimed to design a Fixed-dose tablet formulation of Metformine and Repaglinide.
📊
Temel Bulgular & Veri:This new formulsation dissolution results showed that Repaglinide and Metformin HCl dissolved more than 85% from film tablets at 15 minutes.
💡
Sonuç & Katkı:Conclusion: Thus, an alternative product to the market product was developed.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Fixed-Dose Tablet · Metformin · Repaglinide

Abstract

Background and Aims: The study aimed to design a Fixed-dose tablet formulation of Metformine and Repaglinide. Methods: Wet granulation method was used to prepare tablet formulations. Characterization studies and dissolution studies were performed. Results: A stable formulation was developed according to the requirements of the pharmacopoeia criteria. This new formulsation dissolution results showed that Repaglinide and Metformin HCl dissolved more than 85% from film tablets at 15 minutes. Conclusion: Thus, an alternative product to the market product was developed.

🔖

Bu Makaleye Atıf Yap

ŞAHİN, S., MESUT, B., DURGUN, M. E., ÖZÇELİK, E., ÖZSOY, Y. (2021). Preparation and in vitro studies of fixed-dose tablet combination of repaglinide and metformin. İstanbul Journal of Pharmacy, Cilt: 51 - Sayı: 1, 26–34. https://ajindex.com/articles/161881

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Abbink, E. J., van der Wal, P. S., Sweep, C. G. J. (Fred), Smits, P., & Tack, C. J. (2004). Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. Diabetes/Metabolism Research and Reviews, 20(6), 466–471. https://doi.org/10.1002/dmrr.474 • American Diabetes Association. (2000). Type 2 Diabetes in children and adolescents. Pediatrics, 105(3), 671–680. https://doi. org/10.1542/peds.105.3.671 • American Diabetes Association. (2015). Classification and diagnosis of diabetes. Diabetes Care, 38(Supplement_1), S8–S16. https:// doi.org/10.2337/dc15-S005 • Cicero, A. F. G., Tartagni, E., & Ertek, S. (2012). Mini-Special issue paper management of diabetic patients with hypoglycemic agents metformin and its clinical use: new insights for an old drug in clinical practice. Archives of Medical Science, 5, 907–917. https:// doi.org/10.5114/aoms.2012.31622 • Czyzyk, A., Tawecki, J., Sadowski, J., Ponikowska, I., & Szczepanik, Z. (1968). Effect of biguanides on intestinal absorption of glucose. Diabetes, 17(8), 492–498. https://doi.org/10.2337/diab.17.8.492 • EMA. (2010). Guideline on the investigation of bioequivalence. Retrieved from https://www.ema.europa.eu/en/documents/ scientific-guideline/guideline-investigation-bioequivalencerev1_ en.pdf • European Pharmacopeia 6. Uniformity of mass of singledose preparations. Retrieved from %2020907e.pdf • FDA. 2009. Dissolution methods. Retrieved from https://www. accessdata.fda.gov/scripts/cder/dissolution/dsp_getalldata.cfm • Gautam, C. S., & Saha, L. (2008). Fixed dose drug combinations (FDCs): rational or irrational: a view point. British Journal of Clinical Pharmacology, 65(5), 795–796. https://doi.org/10.1111/j.1365- 2125.2007.03089.x • Godman, B., McCabe, H., & D Leong, T. (2020). Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research, 20(1), 1–26. https://doi.org/10.1080/14737167.2020.1734456 • Hasslacher, C. (2003). Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care, 26(3), 886–891. https://doi.org/10.2337/diacare.26.3.886 • Hostalek, U., Gwilt, M., & Hildemann, S. (2015). Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs, 75(10), 1071–1094. https://doi.org/10.1007/s40265-015-0416-8 • ICH. (2003)